Q-omics provides the consensus-scored EIF2S2P4 profile across patient tissues and cancer cell-line models. EIF2S2P4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, EIF2S2P4 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, EIF2S2P4 RNA expression shows 16,552 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, COAD, and ACC as cancer lineages where EIF2S2P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF2S2P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF2S2P4 survival associations across molecular data types. EIF2S2P4 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF2S2P4 RNA expression–survival associations across cancer types. High EIF2S2P4 expression shows unfavorable associations in PAAD, UVM, KIRP, ACC and BRCA, but favorable associations in READ. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for EIF2S2P4 RNA expression.
This table summarizes EIF2S2P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF2S2P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF2S2P4 shows higher tumor expression in COAD, STAD, HNSC, LIHC, BRCA and LUAD. The COAD box plot shows higher EIF2S2P4 RNA expression in tumor versus normal tissue (log2 FC = +1.562, t-test p < 0.001).
This table shows molecular features associated with EIF2S2P4 in patient tissues and cancer cell lines. In patient samples, EIF2S2P4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
